%0 Journal Article
%T Body Composition, Gynecologic-Obstetric Variables, and Prolactin Levels in Patients with Breast Cancer
%A Luis-Alfredo Jim¨¦nez-Huerta
%A Mar¨ªa-del-Coraz¨®n-de-Jes¨²s Huerta-Franco
%A ¨¢ngel-Haziel Vargas-Huerta
%A Francisco-Miguel Vargas-Luna
%A Mar¨ªa-Raquel Huerta-Franco
%J Food and Nutrition Sciences
%P 315-327
%@ 2157-9458
%D 2023
%I Scientific Research Publishing
%R 10.4236/fns.2023.144021
%X <span><b><span style=\"font-family:&quot;\">Objective:</span></b></span><span><span><span style=\"font-family:&quot;\"> The aim of this study was to determine body composition, gynecological,
and obstetric data, sex hormones, and prolactin serum levels in pre- (PREW) and
postmenopausal women (PMW) with breast cancer (BC) and compare them with a
control group (CG) of healthy women.</span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span><span><b><span style=\"font-family:&quot;\">Methodology</span></b></span></span><span><span><b><span style=\"font-family:&quot;\">:</span></b></span></span><span><span><span style=\"font-family:&quot;\"> <span>BC patients
without treatment or use of hormone replacement therapy, or</span> <span>hormonal birth control, and without data of
metastasis were included. CG</span> w</span></span></span><span><span><span style=\"font-family:&quot;\">as</span></span></span><span><span><span style=\"font-family:&quot;\"> matched for age, BMI, and menstrual cycle status. FSH, LH, E<sup>2</sup>,
progesterone, testosterone, and prolactin (PRL) were measured using
radioimmunoassay kits. Comparisons between BC and CG were made with ¡°<i>t</i>¡±
tests, and with the Mann-Whitney U</span></span></span><span><span><span style=\"font-family:&quot;\">-</span></span></span><span><span><span style=\"font-family:&quot;\">test;<b> </b><i>¦Ö</i><sup>2</sup> test was used to
compare the qualitative variables between the groups. <b>Results</b></span></span></span><span><span><b><span style=\"font-family:&quot;\">:</span></b></span></span><span><span><span style=\"font-family:&quot;\"> Seventy-two patients with BC, and 74 <span>CG women were evaluated. Both groups presented
overweight data, BMI </span>(kg/mt<sup>2</sup>) = 27.21 ¡À 5.51 vs. 28.40 ¡À
4.66, p = ns, for BC patients and CG, respectively. In PREW, the age at
menarche was later in BC patients compared to the CG (13.3 ¡À 1.36 years vs.
12.41 ¡À 1.27 years, p = 0.005). The PMW with BC presented a higher age at
menarche and menopause compared to the women of the CG (13.51 ¡À 1.48 vs. 12.91
¡À 1.41, p = 0.09, and 49.03 ¡À 2.86 vs. 45.5 ¡À 8.78, p = 0.03, respectively).
PRL levels were significantly higher in <span>PMW
with BC, in comparison with the CG; median and minimum and</span> maxi<span>mum values (min-max) were: 14.7 ng/mL (3.6</span></span></span></span><span><span><span style=\"font-family:&quot;\"> </span></span></span><span><span><span style=\"font-family:&quot;\">-</span></span></span><span><span><span style=\"font-family:&quot;\">
%K Breast Cancer
%K Sex Hormones
%K Prolactin
%K Postmenopausal Women
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=124302